# Programming immunity in situ: A new frontier of in vivo cell engineering

- **DOI:** [10.1126/sciimmunol.aed1027](https://doi.org/10.1126/sciimmunol.aed1027)
- **Rating:** Sound (3.6 out of 5)
- **Verdict:** An integrated review maps delivery and safety choices for in vivo immune-cell engineering, but unreported source selection limits confidence in its evidence coverage.
- **Framework version:** v5.10
- **Pipeline version:** v0.4
- **Evaluation date:** 2026-11-06
- **Evaluation page:** https://www.nabu.science/paper/10.1126%2Fsciimmunol.aed1027

## Key claims

1. In vivo immune cell engineering has entered clinical testing, but its development remains at an early stage.
   - Support: Supported
   - Type: Primary finding
   - Basis: small early-phase clinical cohorts establish feasibility rather than durable, reproducible clinical benefit
   - Location: Conclusions
2. The next challenge lies in enhancing precision to ensure that vectors reach the target cell type and tissue, deliver the appropriate payload, and produce desired transient or durable activity.
   - Support: Supported
   - Type: Secondary
   - Basis: recurring delivery and expression constraints across platforms support this qualitative assessment without systematic comparative weighting
   - Location: Abstract
3. ADs [autoimmune diseases] providing the clearest clinical proof of concept for in vivo immune cell engineering.
   - Support: Tentative
   - Type: Secondary
   - Basis: a small SLE cohort with temporary responses does not establish comparative clinical superiority over oncology evidence
   - Location: Disease applications, Autoimmune diseases

## Strengths

- **Linked framework for therapy design choices** Figure 1 connects vector choice, cellular targets, targeting, expression duration, and safety rather than treating them as independent platform features. Table 1 makes the principal vector tradeoffs accessible.
  - Dimension: contribution
  - Location: Figure 1; Table 1; Conclusions
- **Safety setbacks integrated into the argument** The review discusses early adverse events, autoimmune and HIV rebound, off-target delivery, and conflicting insertional-mutagenesis evidence. These findings inform its requirements for monitoring and control.
  - Dimension: methodological rigour
  - Location: Disease applications; Dynamic control to ensure safety; Insertional mutagenesis
- **Limitations connected to clinical design decisions** Transient versus durable expression is tied to disease context, while the inability to quality-control engineered cells beforehand is linked to patient selection and outcome variability.
  - Dimension: positioning
  - Location: Conclusions

## Limitations

- **Literature selection and appraisal remain unreported** No search, inclusion, prioritization, or appraisal process is described despite extensive clinical and preclinical synthesis. Readers cannot determine how representative the selected evidence is.
  - Dimension: methodological rigour
  - Location: Article-wide source-selection reporting
- **Clinical evidence draws on uneven sources** Clinical statements rely partly on conference abstracts and news reports, and the VERVE-102 LDL reduction is cited to a company announcement. These sources are not consistently graded against peer-reviewed clinical evidence.
  - Dimension: methodological rigour
  - Location: Disease applications; References 9, 10, 98, 103
- **Clinical maturity limits immediate practical use** The clinical signals come from small early-phase studies, while most applications beyond T cells remain preclinical. The synthesis guides development choices but does not establish reproducible benefit or broad deployment readiness.
  - Dimension: application pathway
  - Location: Cellular targets; Disease applications; Conclusions

## Reliability checks

Caveats (4 of 4 checks).

- **Results check:** Clean. The reported numbers and statistics are consistent with the stated results.
- **Reporting and transparency:** Noted. The LDL cholesterol reduction reported for VERVE-102 is sourced to a company announcement rather than a peer-reviewed clinical report. Competing interests are disclosed.
  - Conflict of interest: declared
- **Reference integrity:** Clean
  - 187 references in manuscript
  - 183 of 183 checkable references found in an index
  - 4 are books, websites or datasets — counted, but not index-checkable
  - References not verified automatically are resolved manually within 24 hours.

## Post-publication record

- **Status:** Clean
- **Summary:** No retraction or expression of concern found in Crossref (includes Retraction Watch).
- **Last checked:** 2026-11-06
